I think Frazer didnt fit with the board's views on various issues. I suspect the biggest issue was along the lines of taking on a "bigger" US trial when they couldnt get the "smaller" planned trial off the ground. The word I heard was that there was some interference from major shareholders wanting the trial to be bigger and US centric.
Next thing that happens is new CEO and out goes Frazer...
but at the same time we have seen a disappointing drop off in communication from the company in terms of the Investor newsletters and it doesnt instill confidence.
It was bad luck on the HCC announcement, but they could have played that card much much earlier - let alone talking about secondary cancers to the liver.
They just seem to have lost the team approach that Frazer put in place. Not surprising when the board does the disruption - but they should also be doing some leadership.
You will see on the SRX thread that we have been chatting about another competitor in that space already.
Yet - we hear very little from the company on the advantages of Oncosil over spheres procedurally, technically, safety and any other advantages. In fact on the SRX thread there are some very well informed holders who have their negative views on OSL both on HC and more publically on a blog that TitusPullo put me on to.
Interesting reading and whilst I dont entirely agree, we dont have the company doing much.
My other comment with regards to Frazer was he had significant shares - and I can recall the board removing some to give to the new CEO. ? is he now a seller below our detection threshold. He would know the weaknesses of this company better than anyone.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)